Drug intelligence / Profile preview

apatinib + docetaxel + S-1

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of apatinib, docetaxel, and S-1, being evaluated as a first-line treatment for metastatic gastric cancer. Apatinib is a small-molecule tyrosine kinase inhibitor that highly selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR-2), thereby blocking tumor angiogenesis. Docetaxel is a cytotoxic chemotherapy agent that promotes microtubule assembly and inhibits disassembly, leading to cell cycle arrest. S-1 is an oral fluoropyrimidine combination (tegafur, gimeracil, and oteracil) that acts as an antimetabolite. This specific triple combination is being investigated in a Phase 2 clinical trial (NCT03154983) led by Dr. Zhou Fuxiang at Zhongnan Hospital of Wuhan University to improve progression-free survival in patients with metastatic gastric adenocarcinoma.

Brand names: AitanTaxotereTS-1TS1TS 1Teysuno
Other names: apatinib mesylate + docetaxel + S-1apatinib + docetaxel + tegafur-gimeracil-oteracil

Targets

ABCB1 (P-glycoprotein)VEGFR2 (Vascular endothelial growth factor receptor 2)TUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)

Beyond the preview

Go deeper on apatinib + docetaxel + S-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on apatinib + docetaxel + S-1.

Explore the full profile